Literature DB >> 18940575

Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes.

Francisco A Bonilla1.   

Abstract

This article reviews pharmacokinetic studies of IgG administration by intravenous and subcutaneous routes. Intravenous immunoglobulin pharmacokinetics have been studied during replacement therapy for primary and secondary immunodeficiencies and other special circumstances (eg, infection prophylaxis in neonates). Subcutaneous immunoglobulin pharmacokinetics have been studied only during replacement therapy for primary immunodeficiency. Published studies vary greatly with respect to the nature of the patients studied, dose regimens, sampling schedules, and pharmacokinetic models, making comparisons difficult. With either route of administration, there is large variation in individual IgG elimination rates. Periodic measurement of serum IgG concentration is critical to monitor the adequacy of replacement during therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18940575     DOI: 10.1016/j.iac.2008.06.006

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  53 in total

1.  Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels.

Authors:  Sylvain Thépot; Marion Malphettes; Anaëlle Gardeur; Lionel Galicier; Bouchra Asli; Lionel Karlin; Laurence Gérard; Richard Laumont; Marie-Laure Doize; Bertrand Arnulf; Claire Fieschi; Djaouïda Bengoufa; Eric Oksenhendler
Journal:  J Clin Immunol       Date:  2010-07       Impact factor: 8.317

2.  International Consensus Document (ICON): Common Variable Immunodeficiency Disorders.

Authors:  Francisco A Bonilla; Isil Barlan; Helen Chapel; Beatriz T Costa-Carvalho; Charlotte Cunningham-Rundles; M Teresa de la Morena; Francisco J Espinosa-Rosales; Lennart Hammarström; Shigeaki Nonoyama; Isabella Quinti; John M Routes; Mimi L K Tang; Klaus Warnatz
Journal:  J Allergy Clin Immunol Pract       Date:  2015-11-07

3.  Incidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDD.

Authors:  Melvin Berger
Journal:  J Clin Immunol       Date:  2011-06-04       Impact factor: 8.317

Review 4.  Subcutaneous immunoglobulin: opportunities and outlook.

Authors:  S Misbah; M H Sturzenegger; M Borte; R S Shapiro; R L Wasserman; M Berger; H D Ochs
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

5.  Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency.

Authors:  H B Niebur; C M Duff; G F Shear; D Nguyen; T K Alberdi; M J Dorsey; J W Sleasman
Journal:  Clin Exp Immunol       Date:  2015-07-07       Impact factor: 4.330

Review 6.  Chronic Diarrhea in Common Variable Immunodeficiency: a Case Series and Review of the Literature.

Authors:  Antonio Pecoraro; Liliana Nappi; Ludovica Crescenzi; Francesco P D'Armiento; Arturo Genovese; Giuseppe Spadaro
Journal:  J Clin Immunol       Date:  2017-11-14       Impact factor: 8.317

7.  Regulation of the Human Fc-Neonatal Receptor alpha-Chain Gene FCGRT by MicroRNA-3181.

Authors:  Daniel C Ferguson; Javier G Blanco
Journal:  Pharm Res       Date:  2018-01-04       Impact factor: 4.200

Review 8.  Pharmacokinetic modeling of therapies for systemic lupus erythematosus.

Authors:  Xiaoyan Yang; Catherine M T Sherwin; Tian Yu; Venkata K Yellepeddi; Hermine I Brunner; Alexander A Vinks
Journal:  Expert Rev Clin Pharmacol       Date:  2015-07-09       Impact factor: 5.045

9.  Bioavailability of IgG administered by the subcutaneous route.

Authors:  Melvin Berger; Stephen Jolles; Jordan S Orange; John W Sleasman
Journal:  J Clin Immunol       Date:  2013-03-01       Impact factor: 8.317

10.  Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease.

Authors:  Suzanne Skoda-Smith; Troy R Torgerson; Hans D Ochs
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.